Clinical Trials in Nashville

Showing 7441-7460 of 15,379 trials

A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial

NCT04263987

Holmium laser enucleation of the prostate (HOLEP) has proven to be efficacious and safe for the treatment of benign prostatic hypertrophy (BPH). New laser technologies such as the Moses Pulse laser system provide for improved energy delivery which may decrease blood loss and operative time. We seek to evaluate Moses technology for enucleation of the prostate in the setting of BPH.

Benign Prostatic Hyperplasia

Vanderbilt University Medical Center60 participantsStarted Jan 2020

Nashville, Tennessee, United States

COMPLETEDPhase 1< 1 mile

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664

The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Novartis Pharmaceuticals283 participantsStarted Aug 2016

Baltimore, Maryland, United States • Boston, Massachusetts, United States • Nashville, Tennessee, United States +20 more locations

A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Find Trials by Condition in Nashville

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Repeat Antenatal Steroids Trial

The National Standard for Normal Fetal Growth

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

PERL Continuous Glucose Monitoring (CGM) Study

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Post Market Study of the 3DKnee™ With E-plus Insert

Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Combination Study for High Risk Multiple Myeloma Patients